Fcrn antibodies and methods of use thereof

A method of treating myasthenia gravis in a patient in need thereof, the method comprising administering an initial loading dose of about 30 mg/kg mg/kg to about 60 mg/kg of an anti-FcRn antibody followed by administering a maintenance dose of about 15 mg/kg to about 30 mg/kg of the anti-FcRn antibody, wherein the anti-FcRn antibody comprises:

• a heavy chain comprising a HCDR1 of SEQ ID NO:
• 6, a HCDR2 of SEQ ID NO:
• 7, and a HCDR3 of SEQ ID NO:
• 8;
• and
• a light chain comprising a LCDR1 of SEQ ID NO:
• 3, a LCDR2 of SEQ ID NO:
• 4, and a LCDR3 of SEQ ID NO:
• 5;
• wherein the administration reduces serum IgG in the patient by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of baseline serum IgG.